Program 18 November 2020

CET SETTING THE SCENE OF AMR R&DPresenting:Affiliation:
09:30Fighting Infectious Diseases to support UN SDG at KIT Royal Tropical InstituteMrs Lindy van VlietRoyal Tropical Institute; NL
09:40AMR: 6 Key Strategies to curb the global threatDr Maarten van DongenAMR Insights; NL
10:00WHO’s update in priority setting for AMR R&DDr Sarah PaulinWHO; CH
10:20– Coffee break –
10:30The Dynamic Dashboard of the Global AMR R&D Hub: towards evidence-based decision making Dr Elmar NimmesgernGlobal AMR R&D Hub; Germany
10:50Proposals for increasing, accelerating and bettering R & D of new antibacterials in the context an adverse marketDr Arielle Blocker

Evotec; F

11:10AMR Action Fund: Strengthening and accelerating antibiotic developmentDr Silas HollandAMR Action Fund; USA
11:30Data technologies in diagnostics and treatment of AMR Dr John HaysErasmus Medical Center; NL
11:50The COVID-19 pandemic and its effect on AMR: a global perspectiveDr Yarah Mohsen Joint Commission International accredited Hospital; Egypt
12:10Emerging New Technologies to Fight AMR and COVID-19’s Effect on Rapid Testing InnovationDr Gyorgy AbelLahey Hospital & Medical Center/ Harvard Medical School; USA
12:30COVID-19 & AMR: the launch of a novel retrospective multi-country study Dr Maarten van Dongen AMR Insights; NL
12:35 – Lunch break –
TECHNOLOGY AND PRODUCT UPDATES IN AMR
01:00Guanidino Lipoglycopeptides: Novel Glycopeptide Antibiotics with Best-in-Class PotentialProf Nathaniel MartinLeiden University; NL
01:20Synergy between peptide D8 and common antibiotics to fight Gr- pathogensDr Auke van HeelOmnicin Therapeutics; NL
01:40Making aminoglycosides great againDr Sven HobbieJuvabis; CH
02:00Novel mode of action against MDR Neisseria gonorrhoeaeDr Pascal MayerAlphanosos; France
02:20Efflux avoidance strategy for developing novel antibacterialsDr Santanu DattaBugworks; India & USA
02:40Driving change to using microbial diagnostics: the launch of a new serious gameGerard Mulder MindGame; NL
03:00Microfluidic methods in phenotypical and molecular diagnostics to curb AMRDr Seweryn Bajer-BorstynScopeFluidics; Poland
03:20The Role of Rapid Diagnostic Tests in Antimicrobial Stewardship to combat Antimicrobial Resistance – A lower middle income country perspectiveDr Vindana ChibabhaiCharlotte Maxeke Johannesburg Academic Hospital; SA
03:40The Antimicrobial Resistance Fighter CoalitionDr Diane FlayhartBecton, Dickinson and Company; USA
03:50– Coffee break –
ACCELERATING AMR R&D
04:00Addressing the development of treatments for priority drug resistant infectionsDr Seamus O’BrienGARDP; CH
04:20CARB-X: Supporting innovation to address drug resistant bacteriaDr Nadia CohenCARB-X; USA
04:40Future of Diagnostics R&DDr Betsy Wonderly TrainorCARB-X; USA
05:00Global partnering in AMR R&DDr Maarten van DongenAMR Insights; NL
05:20AMR Innovation Mission UK 2021Dr Peter DirkenInnovate UK; UK
05:40Closing remarksDr Maarten van DongenAMR Insights; NL
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!